Bicara Therapeutics (BCAX) Capital Expenditures (2023 - 2026)

Bicara Therapeutics has reported Capital Expenditures for 4 years, with the latest figure at $60000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $60000.0; the trailing twelve-month figure through Mar 2026 stood at $340000.0 (up 407.46% YoY), and the FY2025 full-year result was $280000.0, up 294.37% from the prior year.
• Capital Expenditures for Q1 2026 stood at $60000.0, down from $238000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $436000.0 in Q4 2023, with the low at $4000.0 in Q1 2024.
• Historically, Capital Expenditures has averaged $105875.0 across 4 years, with a median of $41000.0 in 2024.
• Annual changes were most pronounced in 2024 — Capital Expenditures slumped 90.83% — and 2025, when it jumped 495.0%.
• Bicara Therapeutics' Capital Expenditures stood at $436000.0 in 2023, then tumbled by 90.83% to $40000.0 in 2024, then jumped by 495.0% to $238000.0 in 2025, then slumped by 74.79% to $60000.0 in 2026.
• The last three Capital Expenditures figures came in at $60000.0 (Q1 2026), $238000.0 (Q4 2025), and $42000.0 (Q3 2025), per Business Quant data.